Uncategorized
Melanoma Research Alliance Statement on FDA Approval of Tebentafusp, the First Drug for Treating Metastatic Uveal Melanoma
WASHINGTON--(BUSINESS WIRE)--The Melanoma Research Alliance (MRA) released the following statements from MRA Chief Science Officer Marc Hurlbert, PhD and MRA President & CEO Michael Kaplan on the Food & Drug Administration approval of tebentafusp, the first drug for treating metastatic uveal melanoma: MRA Chief Science Officer Marc Hurlbert, PhD: “This approval represents a new day for patients and families affected by uveal melanoma. Previously, patients facing metastatic uveal melanom